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Abstract
Background To compare the tolerability of commonly
prescribed topical glaucoma medications by determining
frequency and bother of side effects, patient satisfaction
with their medication, and the chance of discontinuation of
eye drops.
Methods The tolerability of topical glaucoma medication
was studied in glaucoma patients from nine hospitals. The
frequency and severity of side effects was investigated
together with patient satisfaction with the medication and
the probability to change medication due to reported side
effects. To register side effects of topical glaucoma
medication, patients were requested to fill in a questionnaire
based on “the Comparison of Ophthalmic Medications for
Tolerability” (COMTOL) questionnaire supplemented with
items based on the most frequently observed and severe
side effects.
Results The number of patients responding was 3,333
(87%). Most patients (79%) were satisfied with their eye
medication. The median score for ocular side effects was 58
on a scale ranging from 0 to 320. The probability that
medication would be changed by the ophthalmologist at the
next visit due to reported side effects occurring since the
patients’ last or last but one visit to the ophthalmologist was
9%. The most frequently prescribed drugs were timolol,
latanoprost, and the fixed combinations of dorzolamide/
timolol (Cosopt®) and latanoprost/timolol (Xalcom®). Only
small differences in tolerability were found between these
drugs.
Conclusions The tolerability of timolol, latanoprost, and
the fixed combinations of latanoprost/timolol (Xalcom®)
and dorzolamide/timolol (Cosopt®) seem to be comparable.
Patients are satisfied with their glaucoma medication and
have a low chance of discontinuation of eye drops due to
side effects.
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Introduction
Side effects of glaucoma medication are frequently docu-
mented in case reports in a small series of patients without
any comparison to other drugs. A comparison of tolerability
between drugs can be made in a randomized controlled
trial, but usually the comparison is made between only two
drugs: a new glaucoma drug and one that has been
available for a longer period of time. Such studies are
generally performed in ideal circumstances with a selection
of healthier patients and with standardized reporting of
adverse events including systematic questioning of patients,
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which may perhaps not reflect daily life. The scientific
literature on adverse events of glaucoma medication is also
limited because most often only one assessment method is
used.
A useful method to study the side effects of glaucoma
medication would be to combine clinical observations or
measurements of side effects with more subjective measure-
ments, such as assessing the patients’ perspective with
respect to side effects with a “patient reported outcome”
(PRO) instrument. Additionally, directly comparing all
commonly prescribed glaucoma medication in a large
patient population may reflect a real life situation.
In the present study, the results of a patient questionnaire
registering frequency and bother of side effects of different
drugs and patient satisfaction with their medication were
studied together with the probability of changing topical
glaucoma therapy by ophthalmologists due to reported side
effects, in the same study population of 3,841 glaucoma
patients from nine Dutch hospitals.
Materials and methods
Sample and setting
The data from 3,841 patients who were recruited from nine
centers (academic, teaching, and non-teaching hospitals)
participating in the DUtch Research project on treatment
outcome IN Glaucoma patients (DURING) study were used
[1, 2]. The DURING study population consisted of
glaucoma patients who already used or started to use
glaucoma medication. Patients were enrolled between
March 2001 and January 2004. The mean age±standard
deviation of patients included was 69±12 years, ranging
from 21 to 97 years, 1,920 (50%) were male. The majority
of patients (85%) were diagnosed with open-angle glauco-
ma (69%), ocular hypertension (9%), or glaucoma suspect
(7%).
Variables and measurements
The side effects of topical glaucoma medication were
registered by asking patients to fill in a questionnaire based
on “the Comparison of Ophthalmic Medications for
Tolerability” (COMTOL) questionnaire [3]. The COMTOL
questionnaire was designed and validated for comparing the
tolerability of topical glaucoma medications. Since the
COMTOL mainly focuses on side effects of pilocarpine and
timolol, the questionnaire was modified for our present
purpose. Several items were left out, such as items
especially dealing with side effects of pilocarpine and items
dealing with limitation in activities. Items dealing with
compliance were also left out since it was not the purpose
of the present study to thoroughly study compliance. Next,
the questionnaire was supplemented with items listed in the
Farmacotherapeutisch Kompas, a guide for medical therapy
issued by the Dutch Health Care Insurance Board [4]. To
ensure content validity, two glaucoma specialists studied
these listed items independently of each other, after which
the most frequently observed and/or severe side effects of
all commonly used glaucoma medications were included in
the final patient questionnaire. It was taken into account
that patients should be able to notice the side effects
themselves.
The ocular symptoms listed were burning, stinging,
conjunctival hyperaemia, itching, ocular secretion, ocular
pain, tearing, brow ache, dryness, foreign body sensation,
eyelid redness, eyelid oedema, blurred vision, visual acuity
loss, accommodation difficulties, and night vision prob-
lems. For each side effect, the frequency of the symptoms
and the severity of bother for the patient were documented.
The questions concerning the frequency of effects were
graded from ‘Did not experience’, ‘One day’, ‘Several
days’, ‘About half of days’, ‘Almost every day’ and ‘Every
day’ in the preceding 14 days. The questions concerning
the intensity of bother were graded from ‘Not at all
bothered’, ‘A little bothered’, ‘Quite bothered’, ‘Much
bothered’ and ‘Extremely bothered’.
In addition, questions were asked concerning patient
satisfaction with their medication. The patients were asked
to indicate their level of satisfaction on a 7-point scale:
‘Very unsatisfied‘, ‘Unsatisfied’, ‘A little unsatisfied, ‘Not
unsatisfied nor satisfied’, ‘A little satisfied’, ‘Satisfied’ and
‘Very satisfied’.
Procedure
To identify as many patients as possible with recent
changes in their glaucoma medication, consecutive patients,
participating in the DURING study, were asked to fill out
the questionnaire at least twice, each time after a visit to
their ophthalmologist. They were asked to fill out at least
two questionnaires to be able to find reported changes in
response. Only the first questionnaire filled out was used in
the final analysis to prevent double counting of the same
patient. Changes in responses were not analyzed. After
collecting all data, only patients who used their current
glaucoma medication or combination of medications for the
first time since their last or last but one visit to the
ophthalmologist (e.g., new patients or patients switching or
adding medication) were included in the study. This
procedure was chosen to prevent loss to follow-up and to
prevent bias originating from differences between patients
using medications from a shorter or longer period of time.
We wanted to include only subjects that recently started
using a particular drug, since it is to be expected that
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patients who use a certain drug (e.g., timolol) for a longer
period of time experience fewer side effects when com-
pared to patients on newer drugs who have not used this
drug for such a long period. In this latter group, patients
and ophthalmologists are likely to stop the treatment when
patients experience a lot of side effects from the beginning
of their use. This difference between long-term and short-
term users introduces a bias in the comparison of drugs.
The questionnaire was handed to the patients at their
visit to the outpatient department. To provide the patients
with ample time for answering all questions, they were
asked to open the envelope with the questionnaire directly
after arriving home, answer the questions, and return the
questionnaire within 14 days. The questions asked referred
to the period of 14 days preceding their last visit to the
ophthalmologist at the outpatient clinic.
In addition, at each patient visit ophthalmologists
indicated on a form if they had decided to stop glaucoma
medication.
Analysis
The first questionnaires filled out by the patients were used
for analysis. Since patients were considered as satisfied
only when they had indicated to be “Satisfied” or “Very
satisfied” with their eye drops, for the variable ‘patient
satisfaction’ the percentage of patients who filled out
“Satisfied” or “Very satisfied” was calculated.
Table 1 The probability of discontinuing glaucoma medication due to side effects; the percentage of patients not (very) satisfied with their
medication and the percentage of patients who obtained a score of 58 or more on the list of ocular symptoms








Total 1,630 9 960 21 960 58
♦ Timolol 119 8 71 18 71 58
♦ Timolol (gellans) 193 6 115 17 115 44
Timolol (preservative-free) 24 13 18 17 18 39
Betaxolol (Betoptic®) 44 9 30 27 30 60
Betaxolol (Betoptic-S®) 36 17 28 25 28 57
♦ Other β-blockers 14 7 7 0 7 43
Latanoprost 280 8 170 23 170 56
O Bimatoprost 45 13 28 29 28 75
♦ Travoprost 30 3 12 8 12 25
Brimonidine 22 23 14 36 14 50
Dorzolamide 14 14 8 0 8 63
O Brinzolamide 22 23 12 33 12 67
Pilocarpine 13 8 4 0 4 75
Other monotherapy (n<26) 7 29 4 25 4 50
Dorzolamide/timolol (Cosopt®) 164 12 100 16 100 56
Latanoprost/timolol (Xalcom®) 133 5 83 23 83 49
O Pilocarpine/metipranolol; pilocarpine/timolol 16 13 12 25 12 67
Latanoprost/timolol 37 3 18 22 18 83
Latanoprost/Timoptol XE® 30 7 21 14 21 57
Latanoprost/betaxolol (Betoptic®) 14 7 10 0 10 70
Latanoprost/betaxolol (Betoptic-S®) 7 0 6 33 6 67
Latanoprost/carteolol (Teoptic®) 14 14 7 14 7 57
Latanoprost/levobunolol 9 11 3 0 3 67
O Latanoprost/dorzolamide 18 22 9 56 9 89
Latanoprost/brinzolamide 14 21 6 0 6 67
Latanoprost/brimonidine 32 13 20 25 20 50
Latanoprost/dorzolamide/timolol (Cosopt®) 73 5 45 13 45 62
O Latanoprost/timolol/pilocarpine (Timpilo®) 6 17 3 33 3 67
Other combinations of 2 medications (n<26) 153 8 73 19 73 66
Other combinations of 3 or more medications 47 6 23 22 23 87
Chi2-test p=0.12 p=0.40 p=0.03
Medications obtaining at least a median score or doing better on all three parameters are shown in bold (♦). Medications obtaining a lower than
median score on all three parameters are shown in italic (O).
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The items concerning the frequency of side effects were
scored on a scale from 0 to 5. On this scale, 0 represented
‘Did not experience’ and 5 represented ‘Every day’.
Likewise, the items concerning the severity of bother were
scored on a scale from 0 (‘Not at all bothered’) to 4
(‘Extremely bothered’). Both scores were multiplied to
determine the final score per item on ocular side effects.
Next, these final scores per type of side effect were
summed over all types of side effects. This sum was used
to assess the median value. The next step was to calculate
per glaucoma drug the percentage of patients with a lower
or higher score than this median value. For the variable
‘stopping glaucoma medication due to side effects’, the
percentage of visits to the outpatient clinic during which the
ophthalmologist decided to stop the use of a certain
glaucoma medication was calculated. In this analysis, all
the visits during which the ophthalmologist had filled out a
form were included to a maximum of two visits per patient.
The Pearson Chi-square test was used to test for a
statistically significant difference between the drugs. This
test was conducted for every variable of tolerability: chance
of stopping the drug, satisfaction, and reported side effects.
In addition, standardized residuals were calculated if the p-
value of the Pearson Chi-square was smaller than 0.05, to
identify the drug(s) that had a more or less than expected
value of this item for tolerability leading to a statistically
significant difference between the drugs.
Results
The number of patients responding was 3,333/3,841 (87%).
These patients returned at least one questionnaire. From
these, only patients who used their glaucoma medication or
combination of medications for the first time since their last
or last but one visit to the ophthalmologist were included in
the data analysis. The data analysis showed that 79% of
patients were satisfied or very satisfied with their eye
medication. The median score for ocular side effects was 58
on a scale from 0 to 320. The probability of changing
medication due to side effects after a visit to the
ophthalmologist was 9%.
The probability that the use of medication was discon-
tinued by the ophthalmologist due to side effects after each
visit to the outpatient clinic, the percentage of patients who
were not satisfied with their eye drops and the percentage
of patients who obtained a score of 58 or more on the list of
ocular symptoms is shown in Table 1 for every drug
(combination). Although in the table medications obtaining
at least a median score or better are shown in bold, and
medications obtaining a lower than median score on all
three parameters are shown in italic, differences between
medications for the variables “discontinued medication”
(p=0.12) and “unsatisfied” (p=0.40) were not statistically
significant. However, there was a statistically significant
difference for the variable “score of ocular symptoms” (p=
0.03). Further analysis revealed that for timolol gellans, the
standardized residual was greater than 2, implying that
fewer subjects on this medication had reported side effects.
Also, for the group ‘other combination of 3 or more
medications’ the standardized residual was lower than –2,
implying that patients using these combinations reported
more side effects.
The numbers per drug (combinations) were small, and
most (combinations of) medications were reported in less
than 50 questionnaires/visits to the ophthalmologist. Med-
ications that were used by more than 50 patients were
timolol, latanoprost, the fixed combination of dorzolamide
and timolol (Cosopt®) and the fixed combination of
latanoprost and timolol (Xalcom®). Even between these
groups there were no large differences in side effects.
Discussion
In the present study, no statistically significant differences
in tolerability between commonly prescribed topical glau-
coma medications were observed as assessed by the chance
of discontinuing the drug or patient satisfaction. There was
a statistically significant difference for self-reported side
effects. This was due to more reported side effects among
the users of ‘other combinations of three or more
medications’ and fewer reported side effects for the users
of timolol gellans. This was a large study on side effects of
commonly used (combinations of) medications in daily
practice, using patient self-reported questionnaires and the
discontinuation of drugs by the ophthalmologist as a
consequence of side effects. Although a causal relationship
between ocular complaints and discontinuing eye drop
treatment cannot be proven, the ophthalmologists made the
decision to continue or to stop drops on account of their
observations of side effects. However, ophthalmologists
may possibly have had more than one reason to decide to
stop a certain medication. Therefore, it cannot be ruled out
that other motivations, e.g., worsening of visual fields,
could also have influenced their decision to discontinue a
certain drop. Ocular complaints and symptoms were found
to be the main cause for changing the medical regimen by
the ophthalmologists.
Although differences in the amount and nature of side
effects between the investigated glaucoma medications or
combinations of glaucoma medications were found, these
differences were small, even between the medications or
combinations of medications that were used by at least 50
patients. These medications were timolol, latanoprost, the
fixed combination of latanoprost and timolol (Xalcom®)
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and the fixed combination of dorzolamide and timolol
(Cosopt®). These results corroborate published review
studies on glaucoma medication [5–13].
The present results also show that patients are satisfied
or very satisfied with their eye drops. The probability of
changing medication due to side effects was low.
However, patients with combinations of three or more
medications had higher levels of ocular symptoms. Since
the number of glaucoma operations in the Netherlands has
almost halved after the introduction of new glaucoma
medications, it may be that these patients rather accept
more ocular symptoms than undergo glaucoma surgery
[14].
The interpretation that certain complaints or symptoms
leading to a discontinuation of a certain glaucoma medica-
tion are caused by the use of this medication needs to be
carefully made. For example, preservatives in eye drops are
potentially harmful to ocular tissues and may cause allergic
reactions in certain individuals [15, 16]. A preservative-free
drop might have been given to a patient who experienced
side effects presumed to be caused by the preservative in
the drops. In case the side effects did not wear off, the
preservative probably was not the cause of these side
effects. Consequently, the overall score for side effects may
rise to a higher level. Additionally, selection bias could
have occurred because frequently new medications are
especially tried for patients who have experienced side
effects for other drugs. Possibly these patients are more
prone to side effects of eye drops or preservatives in drops.
As far as systemic side effects are concerned, many
commonly presumed adverse effects of beta-adrenergic
blocking agents observed via systemic or ocular adminis-
tration are not supported by published randomized clinical
trials [17]. In the present study, although fewer reported
side effects were found for the users of timolol gellans,
some patients may have stopped taking these drops because
of the presumed systemic side effects. However, we could
not prove a causal relationship since we did not refer
patients for further physical examination.
Finally, several complaints or symptoms (like blurred
vision) may have been caused by other ocular problems.
Ocular side effects related to the use of systemic medi-
cations may also occur[18].
Side effects can possibly be severe [19]. Most side
effects that were registered concerning glaucoma medica-
tions in the present study are reversible. Therefore, patients
are often only temporarily bothered with significant side
effects.
Although this was a fairly large study population, the
medications and combinations of medications that were
investigated were often used by only a small number of
patients, making it difficult to show differences between
drugs. Furthermore, a more detailed interpretation of the
present results is hampered because rare side effects may
have been missed. Therefore, discriminating between the
different glaucoma medications on the ground of rare side
effects is impossible. Additionally, side effects that occur
after a longer follow-up period (e.g., iris pigmentation)
were not found in the present study since we included only
subjects who recently started using their medication.
Further study on side effects of topical glaucoma
medication would be useful; by collecting more data in a
larger study population using patient reporting lists differ-
ences between drugs may become more apparent, causality
may be proven by studying observed changes in reporting
after stopping a drug, a longer follow-up period could
possibly reveal long-term and rare side effects, and a study
of systemic side effects could be set up.
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